DUBLIN – The curious gap in understanding between the FDA and the EMA on which drugs work in Duchenne muscular dystrophy (DMD) and which drugs don't widened last week, as the EMA's Committee on Human Medicinal Products (CHMP) refused to recommend Exondys (eteplirsen) for approval in Europe while granting a label extension to Translarna (ataluren).